Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Single Ascending Dose, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Activity of SAR439459 in Adults With Osteogenesis Imperfecta

NCT05231668 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05231668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05231668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Single Ascending Dose, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Activity of SAR439459 in Adults With Osteogenesis Imperfecta
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Terminated
Start date
August 25, 2022
Completion date
November 12, 2024
Enrollment
16 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

osteogenesis imperfecta